SCHEMBL838396

SCHEMBL838396

FC(F)(F)c1ccccc1-n1ncc2c(Cl)ncnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.42
KCNH2 Q12809 1/20 0.42
XDH P47989 1/20 0.41
CYP17A1 P05093 2/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 2/20 0.40
EGFR P00533 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
SLC2A1 P11166 5/20 0.39
SLC2A2 P11168 5/20 0.39
SLC2A3 P11169 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL838726 0.84 GCK (0.44) GCKKCNH2XDHCYP17A1KDM4E
SCHEMBL25344635 0.83 CYP17A1 (0.56) XDHCYP17A1KDM4ECYP1A2SLC2A1
SCHEMBL12000946 0.82 SLC2A1 (0.53) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL839210 0.81 GCK (0.47) GCKKCNH2KDM4EALDH1A1MEN1
SCHEMBL839657 0.79 SLC2A1 (0.54) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6253182 0.79 MAPT (0.47) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL839707 0.79 MAPT (0.48) GCKKCNH2XDHCYP17A1KDM4E
SCHEMBL25975269 0.77 MAPT (0.53) GCKKDM4EALDH1A1MEN1KMT2A
SCHEMBL838829 0.76 P2RX7 (0.46) GCKKDM4EALDH1A1MEN1KMT2A
SCHEMBL839578 0.76 SLC2A1 (0.56) GCKKCNH2XDHKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005047288-A1 PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-05-26 WO claimed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GCK 1/4885KCNH2 1438/4885XDH 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.